Delving Into Padcev-Keytruda Clinical Performance in Urothelial Cancer to Understand the Potential of ADC Combinations to Reshape Standard of Care Therapies

• Overviewing enfortumab vedotin (EV) and combining with pembrolizumab
• Reflecting on previous clinical data of EV in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
• Exploring recent clinical combination data of EVpembrolizumab combinations with pembrolizumab in muscle-invasive bladder cancer

Speakers:

Jasmine Lichfield

Senior Director, Clinical Research, Oncology

Astellas Pharma